Greenwich LifeSciences (GLSI) EBIT (2019 - 2026)

Greenwich LifeSciences (GLSI) has 7 years of EBIT data on file, last reported at -$7.9 million in Q4 2025.

• Quarterly EBIT rose 18.17% year-over-year to -$7.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$19.4 million (down 10.27% YoY) and the FY2025 annual result came in at -$19.4 million, down 10.27% from the prior year.
• EBIT slipped to -$7.9 million in Q4 2025, from -$4.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$600606.0 in Q1 2021 to a low of -$9.7 million in Q4 2024.
• A 5-year average of -$3.0 million and a median of -$2.5 million in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2021 — EBIT plunged 258.05% — and 2025, when it advanced 18.17%.
• Tracing GLSI's EBIT over 5 years: stood at -$2.4 million in 2021, then decreased by 21.77% to -$2.9 million in 2022, then increased by 2.03% to -$2.8 million in 2023, then slumped by 242.36% to -$9.7 million in 2024, then increased by 18.17% to -$7.9 million in 2025.
• The last three EBIT figures came in at -$7.9 million (Q4 2025), -$4.2 million (Q3 2025), and -$4.0 million (Q2 2025), per Business Quant data.